Also found in: Dictionary, Wikipedia.


an inhibitor of bone resorption used as the sodium salt in the treatment of osteitis deformans and for the prevention and treatment of osteoporosis, administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


A bisphosphonate drug, C7H11NO7P2, that inhibits bone resorption and is used in the form of its sodium salt to treat and prevent osteoporosis in postmenopausal women.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


Actonel® Metabolic disease A biphosphonate used to manage osteoporosis and prevent steroid-induced bone loss Indications Postmenopausal osteoporosis, corticosteroid-induced osteoporosis, Paget's disease of bone. See Osteoporosis, Paget's disease of bone.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.


A bisphosphonate drug used to treat PAGET'S DISEASE. A brand name is Actonel.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005

Patient discussion about risedronate

Q. Why these days in spite of the awareness and knowledge about ADHD, the ADHD patients are on the rise?

A. No …it’s not. I think this growing awareness has made the diagnosis easy and helpful. As previous parents never used to take their child serious for the possibility of any psychological disorders but now they do. Moreover regarding ADHD, now the school teacher and anyone who deals with child are trained to identify the child in their training. Even growing awareness has also paves way for treatment at the correct time before it gets severe.

Q. I feel that my temperature is rising, I am worried as it was told to me to not take on any medicine? I am currently in my 1st trimesters and last week I had fever over 100. I took paracetamol and I got well. Again today I feel that my temperature is rising and it has gone pretty high. My body is on high pain l and I think I must meet a doctor this time. What you guys have to say……I am worried as it was told to me to not take on any medicine but I had taken one ………what can happen?

A. First, congratulations for the pregnancy. I agree with falseact, you should see your OB-GYN doctor for a consult. But here I paste a data that might be useful to calm your worry..

Acetaminophen or paracetamol labeling, like all OTC medications, instructs consumers who are pregnant or nursing a baby to contact their doctor before use. Acetaminophen or paracetamol has been used for over 40 years and available data indicate that acetaminophen in therapeutic doses does not adversely affect the pregnant mother or the fetus.

Q. Rising PSA to 10 with two negative biospies? Expect cancer? 67 yrs old in good health otherwise.

A. High values don't always mean it's cancer. At 67 years old, you're prostate is most likely enlarging, resulting in the higher PSA results. And after two negative biopsies, it sounds like you're in the clear. Like Brandon said though, keep up with your regular check ups.
Source: http://www.northshore.org/healthresources/encyclopedia/encyclopedia.aspx?Version=Q3_08&DocumentHwid=hw5522&ViewHwid=hw5548

More discussions about risedronate
This content is provided by iMedix and is subject to iMedix Terms. The Questions and Answers are not endorsed or recommended and are made available by patients, not doctors.
References in periodicals archive ?
Study results indicated that in the glucocorticoid-continuing subpopulation, Prolia demonstrated a significantly greater increase in lumbar spine bone mineral density compared to risedronate at one year (3.8 percent versus 0.8 percent, respectively) with a treatment difference of 2.9% (p
In conjunction, the Phase 3 study showed that the patients on glucocorticoid therapy who received Prolia had greater gains in bone mineral density (BMD) compared to those who received active comparator (risedronate), Amgen concluded.
VERO, which pitted teriparatide (Forteo) against risedronate in women with at least two moderate or one severe vertebral fracture, as well as a bone mineral density (BMD) T score of -1.5 or less, was the first study to compare an anabolic treatment to antiresorptive therapy using fractures as an endpoint, according to Astrid Fahrleitner-Pammer, MD, of the departments of internal medicine, endocrinology, and diabetology at Medical University of Graz (Austria), who presented the study at the annual meeting of the American Society for Bone and Mineral Research.
Recommendation: Pharmacologic treatment is recommended using alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk of hip and vertebral fractures in women who have known osteoporosis diagnosed as a T score less than--2.5 or those with fragility fracture (strong recommendation with high-quality evidence).
The baseline charac-teristics were comparable between the bisphosphonate group and control group, and the intervention contained zoledronic acid, Alendronate, Risedronate, Etidronate (Table-I).
As a member of the new generation of osteoporosis drugs, risedronate sodium is used for the treatment and prevention of osteoporosis in postmenopausal women.
Those at high risk should be offered pharmacologic therapy, which may include an antiresorptive therapy such as a bisphosphonate (e.g., alendronate, risedronate or zoledronic acid) or denosumab, or a bone-formation therapy, such as teriparatide; however, men with prostate cancer should stay away from bone formation therapy as these therapies may stimulate the growth of malignant cells in bone.
While participants who received risedronate experienced a 70% improvement in bone density in comparison with values obtained prior to treatment, the improvement in the group that received calcium and vitamin D only (the placebo arm) was nearly as great, at 69%.
In the risedronate plus calcium and vitamin D group, researchers observed significant improvement of BMDs in 70% (19/27) of the participants.
Both had a significant decrease in BMD that favoured the delayed ZOL; 3 trials of risedronate and ibandronate also had a significant decrease in BMD in AIs alone group.
Three-year randomized, controlled phase III clinical trials have established that the brand amino-bisphosphonates alendronate [1, 2], risedronate [3, 4], and zoledronic acid [5, 6] are generally safe and provide significant antifracture efficacy at vertebral, nonvertebral, and hip sites.
The guidelines also advocate medical therapy with zoledronic acid or other bisphosphonate drugs--alendronate (Fosamax), risedronate (Actonel), or deno-sumab (Prolia)--or teriparatide (Forteo) for men with a history of hip or spinal fracture and men at high risk of fracture based on DXA results and clinical risk factors.